scholarly journals Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers

2013 ◽  
Vol 32 (05) ◽  
pp. 148-158 ◽  
Author(s):  
Anna S. Berghoff ◽  
Harald Stefanits ◽  
Adelheid Woehrer ◽  
Harald Heinzl ◽  
Matthias Preusser ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Clinical Utility ◽  
Tumor Biomarkers ◽  
Practice Guide ◽  
Levels Of Evidence

scholarly journals Clinical Neuropathology Practice News 4-2012: levels of evidence for brain tumor biomarkers

2012 ◽  
Vol 31 (07) ◽  
pp. 206-209 ◽  
Author(s):  
Anna Sophie Berghoff ◽  
Harald Stefanits ◽  
Harald Heinzl ◽  
Matthias Preusser
Keyword(s):  
Brain Tumor ◽  
Tumor Biomarkers ◽  
Levels Of Evidence

22. Clinical utility of integrated genomic profiling in pediatric brain tumor

2018 ◽  
Vol 226-227 ◽  
pp. 44
Author(s):  
Fumin Lin ◽  
Fengqi Chang ◽  
Lea Surrey ◽  
Gozde Akgumus ◽  
Daniel Gallo ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Clinical Utility ◽  
Pediatric Brain Tumor ◽  
Genomic Profiling ◽  
Pediatric Brain

scholarly journals Clinical Utility of Transcranial Magnetic Stimulation (TMS) in the Presurgical Evaluation of Motor, Speech, and Language Functions in Young Children With Refractory Epilepsy or Brain Tumor: Preliminary Evidence

2021 ◽  
Vol 12 ◽  
Author(s):  
Shalini Narayana ◽  
Savannah K. Gibbs ◽  
Stephen P. Fulton ◽  
Amy Lee McGregor ◽  
Basanagoud Mudigoudar ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Transcranial Magnetic Stimulation ◽  
Motor Cortex ◽  
Young Children ◽  
Magnetic Stimulation ◽  
Clinical Utility ◽  
Refractory Epilepsy ◽  
Speech And Language ◽  
Motor Speech ◽  
Language Functions

Accurate presurgical mapping of motor, speech, and language cortices, while crucial for neurosurgical planning and minimizing post-operative functional deficits, is challenging in young children with neurological disease. In such children, both invasive (cortical stimulation mapping) and non-invasive functional mapping imaging methods (MEG, fMRI) have limited success, often leading to delayed surgery or adverse post-surgical outcomes. We therefore examined the clinical utility of transcranial magnetic stimulation (TMS) in young children who require functional mapping. In a retrospective chart review of TMS studies performed on children with refractory epilepsy or a brain tumor, at our institution, we identified 47 mapping sessions in 36 children 3 years of age or younger, in whom upper and lower extremity motor mapping was attempted; and 13 children 5–6 years old in whom language mapping, using a naming paradigm, was attempted. The primary hand motor cortex was identified in at least one hemisphere in 33 of 36 patients, and in both hemispheres in 27 children. In 17 children, primary leg motor cortex was also successfully identified. The language cortices in temporal regions were successfully mapped in 11 of 13 patients, and in six of them language cortices in frontal regions were also mapped, with most children (n = 5) showing right hemisphere dominance for expressive language. Ten children had a seizure that was consistent with their clinical semiology during or immediately following TMS, none of which required intervention or impeded completion of mapping. Using TMS, both normal motor, speech, and language developmental patterns and apparent disease induced reorganization were demonstrated in this young cohort. The successful localization of motor, speech, and language cortices in young children improved the understanding of the risk-benefit ratio prior to surgery and facilitated surgical planning aimed at preserving motor, speech, and language functions. Post-operatively, motor function was preserved or improved in nine out of 11 children who underwent surgery, as was language function in all seven children who had surgery for lesions near eloquent cortices. We provide feasibility data that TMS is a safe, reliable, and effective tool to map eloquent cortices in young children.

scholarly journals Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression

2018 ◽  
pp. 1-17 ◽  
Author(s):  
Alexey Stupnikov ◽  
Paul G. O’Reilly ◽  
Caitriona E. McInerney ◽  
Aideen C. Roddy ◽  
Philip D. Dunne ◽  
...  
Keyword(s):  
Gene Expression ◽  
Brain Tumor ◽  
Clinical Utility ◽  
Gene Signature ◽  
Sequencing Depth ◽  
Rna Seq ◽  
Data Loss ◽  
Target Compound ◽  
Gene Signatures ◽  
Connectivity Mapping

Purpose Gene expression profiling can uncover biologic mechanisms underlying disease and is important in drug development. RNA sequencing (RNA-seq) is routinely used to assess gene expression, but costs remain high. Sample multiplexing reduces RNA-seq costs; however, multiplexed samples have lower cDNA sequencing depth, which can hinder accurate differential gene expression detection. The impact of sequencing depth alteration on RNA-seq–based downstream analyses such as gene expression connectivity mapping is not known, where this method is used to identify potential therapeutic compounds for repurposing. Methods In this study, published RNA-seq profiles from patients with brain tumor (glioma) were assembled into two disease progression gene signature contrasts for astrocytoma. Available treatments for glioma have limited effectiveness, rendering this a disease of poor clinical outcome. Gene signatures were subsampled to simulate sequencing alterations and analyzed in connectivity mapping to investigate target compound robustness. Results Data loss to gene signatures led to the loss, gain, and consistent identification of significant connections. The most accurate gene signature contrast with consistent patient gene expression profiles was more resilient to data loss and identified robust target compounds. Target compounds lost included candidate compounds of potential clinical utility in glioma (eg, suramin, dasatinib). Lost connections may have been linked to low-abundance genes in the gene signature that closely characterized the disease phenotype. Consistently identified connections may have been related to highly expressed abundant genes that were ever-present in gene signatures, despite data reductions. Potential noise surrounding findings included false-positive connections that were gained as a result of gene signature modification with data loss. Conclusion Findings highlight the necessity for gene signature accuracy for connectivity mapping, which should improve the clinical utility of future target compound discoveries.

Parent-reported cognition and its clinical applications in pediatric oncology.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 9532-9532
Author(s):  
Jin-Shei Lai ◽  
Kevin R. Krull ◽  
Frank Zelko ◽  
Lynne I. Wagner ◽  
David Cella ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Cognitive Function ◽  
Parent Education ◽  
Cognitive Abilities ◽  
Clinical Utility ◽  
Child Gender ◽  
Cluster Membership ◽  
Neurocognitive Assessment ◽  
Cancer Types ◽  
Perceived Cognitive Function

9532 Background: Parent-reported cognitive function (PCF) of their child's cognitive abilities is often used to trigger referral for comprehensive neuropsychological evaluation. The purpose of this study was to evaluate the clinical utility of PCF to predict impairment as measured by neuropsychological assessment and to identify factors associated with PCF. Methods: 565 patients (53% brain tumor, BT; 47% other types of cancer, non-BT) aged 7-21 (mean=14 yrs; 56% males) and their parents were recruited. 34% received radiation therapy, 72% chemotherapy and 71% surgery. Mean years since diagnosis= 5.7 yrs. PCF was measured using a 43-item pediatric perceived cognitive function item bank (pedsPCF). Parents completed the pedsPCF and a single item to rate their child's quality of life (QOL). Patients completed NINDS-NeuroQOL Depression, PedsQL Fatigue scales and neuropsychological tests (NPT) of psychomotor function, attention, learning and working memory using the CogState. K-Means clustering was used to group patients based on scores of depression, fatigue and pedsPCF. Results: PedsPCF significantly differentiated BT from non-BT, t=5.65, p<.01. Correlations between pedsPCF and NPT ranged from 0-0.66 (BT, < 1 yr diagnosis, psychomotor), depending on BT (vs non-BT), yrs since diagnosis and treatment, and NPT. Three clusters were identified with its own unique characteristics. Specifically, pedsPCF was significantly correlated w/ depression & fatigue for cluster 1; correlated w/ NPT scores for non-BT for cluster 2; and correlated w/ NPT for BT for cluster 3. Cluster membership of patients were significantly differentiated by Karnofsky rating, surgery (yes/no), QOL, parent education, child age, and child gender, but not types of treatment, and grade repetition (yes/no). Conclusions: This is one of the first studies to report an association between perceived cognitive function, using parent ratings, and neuropsychological performance. PedsPCF demonstrated clinical utility in differentiating between children with a brain tumor from children with other cancer types. PedsPCF has the potential to serve as a screening tool to facilitate efficient referral for comprehensive neurocognitive assessment.

Utilizing systematic reviews and meta-analyses effectively to evaluate brain tumor biomarkers

2020 ◽  
Vol 14 (10) ◽  
pp. 817-820
Author(s):  
Victor M Lu ◽  
Ashish H Shah ◽  
Daniel G Eichberg ◽  
Evan M Luther ◽  
Sumedh S Shah ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Systematic Reviews ◽  
Tumor Biomarkers ◽  
Meta Analyses
Sign in / Sign up

Export Citation Format

Share Document